Xspray Pharma: Q1 comment
Research Note
2021-05-06
11:04
Redeye reiterates its Base Case of SEK 170 following today's release of the report for the first quarter of 2021. We provide a brief comment on the financials and highlight the most important events during the period.
FE
Filip Einarsson
Disclosures and disclaimers